Adaptimmune Therapeutics plc, a U.K.-based immunotherapy developer, has agreed to pay Seattle-based start-up Universal Cells Inc. $5.5 million up front and up to $41 million in milestones for an exclusive global license to a gene editing technology that could lead to the creation of new allogeneic T-cell therapies.